← Human Trials & Peer-Reviewed Studies
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial
Plain-language guide to PMID 33879733 (2021): randomized controlled trial study of BNP (Nesiritide) in 3 patients.
Key Facts
- PMID
- 33879733
- Journal
- Medicine
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Pang Z et al. (9 authors)
- DOI
- 10.1097/MD.0000000000025621
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.
This study aimed to investigate the effects of the basic treatment for heart failure and sequential treatment with rh-brain natriuretic peptide (rhBNP) alone or the combination of rhBNP and sacubitril/valsartan.
Why It Was Studied
According to the random number table method, the patients were divided into 3 groups of 100 patients per group: the standard treatment group (treated with an angiotensin-converting enzyme inhibitor, β receptor blocker, and corticosteroid antagonist), rhBNP group (basic treatment combined with rhBNP) and sequential treatment group (basic treatment for heart failure combined with rhBNP followed by sacubitril/valsartan).
Who Took Part
The study group was 3 patients.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Cardiac structure, pulmonary artery pressure, inflammation and oxidative stress in patients with acute heart failure were evaluated.Three hundred patients with acute heart failure were included.
How the Study Was Run
In design terms this was a randomized study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
PubMed files the paper under topics including Acute Disease, Adrenergic beta-Antagonists, Aminobutyrates, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Arterial Pressure and Biomarkers.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 3 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2021 (Medicine), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.